Relationship Between Statin Use and Colon Cancer Recurrence and Survival: Results From CALGB 89803
Authors:
- Kimmie NgKNKimmie Ng
- Shuji OginoShuji Ogino
- Jeffrey A. MeyerhardtJMJeffrey A. Meyerhardt
- Jennifer A. ChanJCJennifer A. Chan
- Andrew T. ChanACAndrew T. Chan
- Donna NiedzwieckiDNDonna Niedzwiecki
- Donna HollisDHDonna Hollis
- Leonard B. SaltzLSLeonard B. Saltz
- Robert J. MayerRMRobert J. Mayer
- A. B. BensonABA. B. Benson
- Paul L. SchaeferPSPaul L. Schaefer
- Renaud WhittomRWRenaud Whittom
Open Access
- 17 August 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in JNCI: Journal of the National Cancer Institute
- Vol. 103 (20) , 1540-1551
Abstract
Although preclinical and epidemiological data suggest that statins may have antineoplastic properties, the impact of statin use on patient survival after a curative resection of stage III colon cancer is unknown. We conducted a prospective observational study of 842 patients with stage III colon cancer enrolled in a randomized adjuvant chemotherapy trial from April 1999 to May 2001 to investigate the relationship between statin use and survival. Disease-free survival (DFS), recurrence-free survival (RFS), and overall survival (OS) were investigated by Kaplan–Meier curves and log-rank tests in the overall study population and in a subset of patients stratified by KRAS mutation status (n = 394), and Cox proportional hazards regression was used to assess the simultaneous impact of confounding variables. All statistical tests were two-sided. Among 842 patients, 134 (15.9%) reported statin use after completing adjuvant chemotherapy. DFS among statin users and nonusers was similar (hazard ratio [HR] of cancer recurrence or death = 1.04, 95% confidence interval [CI] = 0.73 to 1.49). RFS and OS were also similar between statin users and nonusers (adjusted HR of cancer recurrence = 1.14, 95% CI = 0.77 to 1.69; adjusted HR of death = 1.15, 95% CI = 0.77 to 1.71). Survival outcomes were similar regardless of increasing duration of statin use before cancer diagnosis ( Ptrend = .63, .63, and .59 for DFS, RFS, and OS, respectively). The impact of statin use did not differ by tumor KRAS mutation status, with similar DFS, RFS, and OS for statin use among mutant and wild-type subgroups ( Pinteraction = .84, .67, and .98 for DFS, RFS, and OS, respectively). Statin use during and after adjuvant chemotherapy was not associated with improved DFS, RFS, or OS in patients with stage III colon cancer, regardless of KRAS mutation status.Keywords
This publication has 47 references indexed in Scilit:
- Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With CetuximabJAMA, 2010
- KRAS Mutation in Stage III Colon Cancer and Clinical Outcome Following Intergroup Trial CALGB 89803Clinical Cancer Research, 2009
- Statin Use and Risk of Colorectal Cancer in a Cohort of Middle-Aged Men in the USDrugs, 2009
- Cardiovascular Medication Use and Risk for Colorectal CancerCancer Epidemiology, Biomarkers & Prevention, 2008
- Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapyBritish Journal of Cancer, 2007
- Statins and cancer preventionNature Reviews Cancer, 2005
- A phase II study of farnesyl transferase inhibitor R115777 in pancreatic cancer: A Southwest oncology group (SWOG 9924) studyInvestigational New Drugs, 2005
- Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol LevelsNew England Journal of Medicine, 1998
- Regulation of the mevalonate pathwayNature, 1990
- Nonparametric Estimation from Incomplete ObservationsJournal of the American Statistical Association, 1958